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therapy [PDT], photothermal therapy, radiofrequency 
interstitial tumor ablation [RITA], focal laser ablation [FLA]) 
but only limited data have been published on the primary 
PPI. From the technique point of view, PPI is now feasible 
with focal BRT and EBRT. The majority of series include both 
low-dose-rate (LDR) and HDR BRT and only recently 
feasibility of PPI by EBRT has been reported4,5. According to 
the international&interdisciplinary panel consensus6, the 
selection criteria for focal therapy include unilateral low-to-
intermediate risk disease < cT2a (prostate size, tumor 
volume, and topography depend on the ablative technology 
used). As for any other focal therapy, focal RT remains 
investigational until numerous questions are answered: initial 
diagnostic tools to identify DIL (imaging, biopsy), technical 
parameters of focal therapy, follow-up exams and 
scheduling, tumor control (patterns of failure) and toxicity 
profile including erectile dysfunction and quality of life (in 
particular, compared to the whole prostate therapy), 
response evaluation and failure definition (nadir+2 is used, 
but in some series biopsy is routinely performed), salvage 
therapy and cost-benefit. Ongoing trials like NCT013549951 
and NCT00807820 will contribute to further assessment of 
PPI. 
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Purpose/Objective: Image-guided IMRT (IG-IMRT) is 
associated with significant dose reductions to organs at risk 
(OAR) compared to 3D-conformal radiotherapy (3D-CRT) in 
prostate cancer patients. However, clinical data identifying 
the benefits of IG-IMRT in patients treated in daily practice 
are scarce. We compared dose distributions and acute 
gastrointestinal (GI) and genitourinary (GU) toxicity levels of 
prostate cancer patients treated to 78 Gy (39x 2 Gy) with 
either IG-IMRT or 3D-CRT.  
Materials and Methods: A total of 215 patients treated to 78 
Gy with 3D-CRT within a dose escalation trial (1997-2003) and 
260 patients treated with IG-IMRT to 78 Gy in the standard 
arm of a hypofractionation trial (2007-2010) are included in 
this analysis. Applied margins were 10mm (3D-CRT) and 5-
8mm (IG-IMRT), and both used 0 mm towards the rectum for 
the 10 Gy boost. Dose surface histograms of anorectum, anal 
canal and bladder were compared. Furthermore, in both 
trials identical toxicity questionnaires were prospectively 
distributed at baseline, at fraction 20 and 30 and 90 days 
after treatment. Slightly modified RTOG grade ≥1, grade ≥2 
and ≥3 toxicity endpoints were derived directly from the 
patient-reported questionnaires. Univariate (UV) and 
multivariate (MV) binary logistic regression was performed. 
Results: IG-IMRT resulted in significant lower median volumes 
receiving 5- 75Gy (all p values <0.001) for anorectum (Figure 
1a), anal canal and bladder. The mean dose to the anorectum 
was 34.4 Gy vs. 47.3 Gy, 23.6 Gy vs. 44.6 Gy for the anal 
canal and 33.1 Gy vs. 43.2 Gy for the bladder (all p<0.001). 
Acute toxicity reached a maximum at fraction 30 for most 
endpoints, as shown for proctitis grade ≥2/ ≥3 in Figure 1b. 
After adjusting for risk factors at MV analysis, IG-IMRT 
resulted in significantly lower overall GI grade ≥2 RTOG 
toxicity (29% vs. 49%, p=0.002, odds ratio (OR) 0.49) and 
overall GU grade ≥2 toxicity (38% vs. 48%, p=0.009, OR 0.59). 
Significantly lower incidences were reported for the 
endpoints abdominal cramps (34% vs. 46%), tenesmus (49% vs. 
62%), mucous discharge (47% vs. 62%), grade ≥2 proctitis (27% 
vs. 44%), stool frequency ≥6/day (8% vs 19%), and urinary 
frequency ≥12/day (19% vs. 30%) (p values 0.002-0.028). 
Comparable incidences (p values >0.05) were found for 
incontinence (both 27%), diarrhea (both 14%), rectal blood 
loss (12% vs. 20%) and nycturia ≥5/night (23% vs. 27%).  
 
